Τίτλος:
The use of novel oral anticoagulants in cancer patients with venous
thromboembolism
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Venous thromboembolism (VTE) is not uncommon among patients with cancer
and is one of the major causes of mortality and morbidity. Treatment
with low-molecular-weight heparin (LMWH) is effective, yet accompanied
by the need for daily administration of injections for a prolonged time
and (even rarely) thrombocytopenia. The discovery of novel oral
anticoagulants (NOACs) was based on an effort to improve the
pharmacodynamic and pharmacokinetic properties of previous generation
anticoagulants while maintaining efficacy without the need for daily
subcutaneous administration and frequent laboratory monitoring. The
MEDLINE database was searched using PubMed in order to find relevant
studies on the use of NOACs in patients with active malignancy and VTE.
Furthermore, critical reading of references in recently published
studies and reviews was performed. NOACs appear to be at least
equivalent to coumarin anticoagulants in terms of efficacy and safety
and their administration is easier, but data specifically concerning
patients with active malignancy or comparing them to LMWH in this
specific clinical setting are not yet available. Furthermore, patients
with active cancer present several unique characteristics and drawing
conclusions from studies involving other patient groups may not be
appropriate. Specific studies in cancer patients are still pending that
will help decide if NOACs will be the drugs of choice in this group of
patients in need of efficient and simple to administer treatments. (C)
2016 Elsevier Inc. All rights reserved.
Συγγραφείς:
Karakatsanis, Stamatis J.
Roumpi, Aikaterini
Syrigos,
Konstantinos N.
Περιοδικό:
Seminars in Oncology Nursing
Εκδότης:
W B SAUNDERS CO-ELSEVIER INC
Λέξεις-κλειδιά:
Venous thromboembolism; Anticoagulants; Active cancer
DOI:
10.1053/j.seminoncol.2016.11.009
